title: Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease.
abstract: The effect of a four weeks oral treatment with 100 mg isosorbide dinitrate (ISDN) daily on platelet function was evaluated in 40 patients (aged 40-65 years) with proven coronary artery disease. Isosorbide dinitrate decreased platelet reactivity to ADP (p less than 0.001), increased platelet sensitivity to PGI2 (p less than 0.01) while the production of TXB2 from exogenous arachidonic acid substrate and from endogenous substrate were both significantly reduced. Circulating platelet aggregates as measured by the Wu-test were markedly reduced (p less than 0.001) but there was little change in the plasma concentration of the platelet proteins beta-thromboglobulin and platelet factor 4. Overall, platelet activation correlated with smoking, hypertension and a family history of coronary artery disease. The reduced platelet activation seen during treatment with isosorbide dinitrate may contribute to the therapeutic benefit seen with this drug in patients with coronary artery disease.
authors.affiliation: Wilhelm Auerswald-Atherosclerosis Research Group (ASF) Vienna, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Sinzinger
authors.forename: I
authors.initials: I
authors.lastname: Virgolini
authors.forename: J
authors.initials: J
authors.lastname: O'Grady
authors.forename: F
authors.initials: F
authors.lastname: Rauscha
authors.forename: P
authors.initials: P
authors.lastname: Fitscha
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D016718:Arachidonic Acid / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D004347:Drug Interactions; D004730:Endothelium, Vascular / Q000166:cytology; D011464:Epoprostenol / Q000494:pharmacology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D007548:Isosorbide Dinitrate / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects; D010978:Platelet Factor 4 / Q000096:biosynthesis; D012307:Risk Factors; D012907:Smoking; D013928:Thromboxane A2 / Q000096:biosynthesis; D001620:beta-Thromboglobulin / Q000096:biosynthesis
chemical_list: D001620:beta-Thromboglobulin; D016718:Arachidonic Acid; D010978:Platelet Factor 4; D013928:Thromboxane A2; D000244:Adenosine Diphosphate; D011464:Epoprostenol; D007548:Isosorbide Dinitrate